Health Care · Electromedical & Electrotherapeutic Apparatus

CV CapsoVision, Inc SEC Filings & Insider Trading Activity 2026

company
CIK 137832554 filings
Russell 2000

CV at a glance

CapsoVision, Inc (CV, SEC CIK 1378325) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CapsoVision, Inc (CV) reported revenue of $13.6 million (up 15.3% from FY2024) and a net loss of $25.3 million. Diluted EPS was -$1.03.
  • As of September 30, 2026, 14 institutional investment managers tracked by SignalX reported holding CapsoVision, Inc (CV) shares worth $30.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by HARARI ELIYAHOU ET AL on September 18, 2026 of 878,735 shares at $5.69 per share.
  • In the last 90 days, CV insiders reported 4 open-market purchases ($20.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $20.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$13.6M
+15.3% vs prior year
Insiders · 90 days
4 buys · 0 sells
Net +$20.0M
13F holders
14 funds
$30.3M · −1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $3.568M, up $0.030M, approximately 1% YoY, driven by international CapsoCam Plus sales
  • Gross margin 49% vs 54% YoY, with gross profit $1.764M vs $1.914M
  • International sales strongest, up 8%; U.S. sales weakest, down 1%
  • Operating cash use $21.5M through nine months vs $15.2M YoY, with $21.8M cash at September 30
  • CapsoCam Colon 510(k) submission expected fourth quarter 2026, with substantial doubt about funding operations for 12 months

Risk Factors

  • New regulatory risk: OBBBA Medicaid reforms, including estimated $1 trillion federal spending reduction from 2025 through 2034
  • Most material update: substantial doubt about going concern, cash $21.8 million and additional financing likely needed by early 2027
  • FDA clearance risk: second-generation CapsoCam Colon 510(k) submission planned for fourth quarter 2026, with FDA staff reductions potentially causing delays
  • Competitive risk: Ankon’s FDA-cleared small-bowel AI launched before AI Highlights, potentially reducing market share and revenue opportunities
  • Concentration risk: Aureliance represented 11% of nine-month revenue and 23% of accounts receivable at September 30, 2026

AI summary of the CV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results released for quarter ended September 30, 2026
  • Exhibit 99.1 contains CapsoVision’s detailed financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.568M, up from $3.538M, while gross margin fell to 49% from 54%
  • Net loss narrowed to $7.339M, or $0.15 per share, from $7.921M, or $0.17
Filed Sep 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA clearance received September 25, 2026 for AI Highlights, expanding CapsoVision’s U.S. commercial product offering
  • Tool targets suspected small bowel bleeding studies in adults and children over age 2

Item 8.01: Other Events

  • FDA clearance received September 25, 2026 for AI Highlights™, an AI-assisted reading feature
  • Feature integrates with CapsoCam Plus®, potentially strengthening product differentiation
Filed Sep 18, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Registered direct offering of 3,163,444 shares at $5.69, approximately 5% below September 16 market price
  • Approximately $18 million gross proceeds, with closing expected September 18, 2026

AI summaries of CV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CV

Don't miss the next CV filing

  • Alerts as it files. A push when CV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CV, by share count.
  • Ask anything. An AI agent that reads every CV filing and answers with sources.

CV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
HARARI ELIYAHOU ET ALBuySep 18, 2026$5.69
HARARI ELIYAHOU ET ALBuySep 18, 2026$5.69
Shen Ching HangBuySep 15, 2026$5.69
Shen Ching HangBuySep 15, 2026$5.69
HARARI ELIYAHOU ET ALBuyJul 17, 2026$6.73
HARARI ELIYAHOU ET ALBuyJul 8, 2026$6.09
Shields David StanleyAJul 1, 2026-
Kuo Hui YingMJun 30, 2026$7.58

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$11.8M$13.6M
Gross Profit-$6.4M$7.2M
Operating Income--$19.9M-$25.5M
Net Income--$19.9M-$25.3M
Gross Margin-54.2%52.9%
Op. Margin--169.4%-188.3%
Net Margin--169.3%-186.8%
Balance Sheet
Total Assets-$16.8M$18.2M
Equity-$109.8M-$129.5M$13.3M
ROE-15.4%-190.9%
Per Share
EPS-$-9.85$-1.03
Cash Flow
Operating CF--$20.1M-$22.9M
CapEx-$153K$90K

Source: XBRL data in CapsoVision, Inc (CV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202614$30.3M
Q2 202615$30.9M
Q1 202614$22.4M
Q4 202511$5.7M
Q3 202510$1.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 64 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KSep 28, 2026Analysis-
4Sep 23, 2026--
4Sep 23, 2026--
4Sep 23, 2026--
8-KSep 18, 2026Analysis-
4Sep 18, 2026--
8-KAug 18, 2026Analysis-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Jul 21, 2026--
4Jul 10, 2026--
4Jul 7, 2026--
4Jul 2, 2026--
8-KJul 2, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 12, 2026Analysis-
4Jun 3, 2026-

Related Health Care companies

All Health Care →

CV SEC filings: frequently asked questions

Are CV insiders buying or selling?

In the last 90 days, CapsoVision, Inc (CV) officers, directors and 10% owners reported 4 open-market purchases worth $20.0 million by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CV stock?

As of September 30, 2026, the largest CapsoVision, Inc (CV) holders among the 13F filers tracked by SignalX were BlackRock ($15.0 million), Vanguard Capital Management LLC ($8.7 million), State Street Corp ($3.1 million), Vanguard Portfolio Management LLC ($1.6 million), BNY Mellon ($487,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CapsoVision, Inc (CV) reported revenue of $13.6 million (up 15.3% from FY2024) and a net loss of $25.3 million. Diluted EPS was -$1.03. The figures come from the XBRL data in the 10-K.

What did CV report in its latest 8-K?

CapsoVision, Inc (CV) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results released for quarter ended September 30, 2026.

What are the latest CV SEC filings?

CapsoVision, Inc (CV) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 23, 2026.

What is CV's SEC CIK number?

CapsoVision, Inc (CV)'s SEC Central Index Key (CIK) is 1378325. EDGAR lists every CV filing under that number.

Ask anything about CV

The research agent reads CV's filings, financials, insider trades and 13F holders, then answers with sources.